The groundbreaking success of the copyright undeniably transformed the drug landscape, but betting in companies primarily reliant on generic versions presents a uncertain picture. Despite early profits were substantial, the end of read more patents and the rise of less expensive alternatives have diminished market share. Therefore, a thorough evalu